Biohaven Ltd.
Rating
Updated: Aug 26, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develo...
Latest News
11 days ago · prnewswire.com
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient enrollment in the Company's BHV-7000/opakalim epilepsy trials.
12 days ago · barrons.com
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
12 days ago · benzinga.com
FDA Pauses New Enrollment for Biohaven Epilepsy Drug ProgramBiohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead pivotal study in refractory focal epilepsy.
12 days ago · reuters.com
US FDA pauses new enrollment in Biohaven's epilepsy drug trialsBiohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down more than 13% in premarket trading.
25 days ago · fool.com
Why Biohaven Stock Was Rocking the Market This WeekIts partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.
26 days ago · seekingalpha.com
Biohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many LevelsBiohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7 ion channel platform, notably opakalim. This agreement immediately strengthens BHVN's cash position, reduces R&D costs, and extends the funding runway, addressing prior liquidity concerns. I am upgrading BHVN to Buy, citing promising degrader pipeline assets targeting large autoimmune markets and pivotal trial initiations.
26 days ago · zacks.com
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy ProgramBiohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global rights to its Kv7 epilepsy platform, led by opakalim.
27 days ago · benzinga.com
Why Is Biohaven Stock Soaring Wednesday?Biohaven Ltd. (NYSE:BHVN) scored two major wins this week. The company signed a lucrative licensing agreement with SK Biopharmaceuticals Co. Ltd. and secured a legal victory alongside Yale University in a trade-secret dispute.
28 days ago · gurufocus.com
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for EpilepsyBiohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candida
28 days ago · reuters.com
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 millionBiohaven has entered into a licensing agreement with South Korean drug maker SK Biopharmaceuticals for Biohaven's epilepsy drug platform, including Opakalim, for up to $795 million, the companies said in a statement on Wednesday.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BHVN